Product Description
Sepranolone is a powerful neurological compound, produced naturally in the body, that modulates the effects of Allopregnanolone (ALLO). ALLO is a potent neurosteroid implicated in stress- and compulsion-related conditions ranging from Tourette to OCD, ADHD, compulsive gambling, PMDD and essential tremor. (Sourced from: https://asarinapharma.com/sepranolone/)
Mechanisms of Action: GABA Receptor Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Asarina Pharma
Company Location: Europe
Company Founding Year: 2010
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Rett Syndrome|Tourette Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2021-001045-12 |
2021-001045-12 | P2 |
Active, not recruiting |
Tourette Syndrome|Rett Syndrome |
2023-02-22 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/12/2026 |
News Article |
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 |
|
03/09/2026 |
News Article |
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing |
|
03/09/2026 |
News Article |
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer |
|
03/09/2026 |
News Article |
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference |